Bitcoin options open interest decreased marginally by 0.14% to $37.26 billion, with call options holding the majority of both open positions (59.71%) and daily trading volume (54.23%). The most active contract by volume was the $86,000 call expiring on November 27, 2026. The largest open interest contracts were high-strike calls expiring in October 2026, indicating strong investor interest in bullish positions or hedging strategies. This data reflects ongoing active trading and positioning in Bitcoin derivatives on the Deribit exchange.
Bitcoin options open interest and volume data provide context for derivatives market activity. For readers following major cryptocurrencies, Pluang's market snapshot shows that out of 50 priced assets, 5 rose and 43 fell today. Notable movers include SXP down 46.27%, BAL up 11.14%, and DOT down 9.66% with a buy order activity of 52%. Data is as of Oct 24, 2026 17:51 WIB.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
